Next-generation antibiotics for all.
GARDP is a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By carrying out research and development and forging public-private partnerships, GARDP is ensuring that the right antibiotics are developed and reach the people who need them.
Highlights
Turning vision into reality
Why a surge in sexually transmitted infections in Europe should worry everybody
Researchers seek better antibiotics for newborn sepsis amid rising drug resistance
Landmark clinical trial to transform treatment options for newborns with sepsis expands to Asia
DNDi, GARDP, and MMV join forces to accelerate drug development for patients in greatest need
A global health crisis is unfolding.
Every 6 seconds, a life is lost to antimicrobial resistance.
Bacteria are evolving, and existing antibiotics are losing power, making once-treatable infections deadly again.
Antimicrobial resistance (AMR) threatens everyone, everywhere.
Drug-resistant infections have reached an alarming tipping point.
lives lost each year globally, making AMR one of the world’s biggest killers
in AMR deaths by 2050
bacterial infections are resistant to existing antibiotics
Drug-resistant infections, especially those caused by Gram-negative bacteria, are now outpacing our ability to treat them, undermining modern medicine.
And global challenges like conflict, climate change and human migration are compounding the crisis.
A radical shift is urgently needed to tackle AMR.
GARDP is countering drug resistance.
The global antibiotic pipeline is drying up and remains off course. Of the 90 antibacterials in development today, only five are both innovative and tackle pathogens of greatest threat to public health.
GARDP is developing next-generation antibiotic treatments, particularly those that are effective against the most difficult-to-treat Gram-negative infections.
GARDP is making the right antibiotics available, where they are needed the most, by factoring access into every stage of antibiotic development. Its work ranges from scientific discovery and R&D to supporting the manufacturing, registration and introduction of treatments.
partners across 27 countries driving innovation and access.
treatments in development targeting WHO priority pathogens.
pre-clinical compounds screened.
in-licensing agreements.
Media coverage
Indian newborns join global race to beat deadly drug-resistant sepsis
Read more
Researchers seek better antibiotics for newborn sepsis amid rising drug resistance
Read more
Global Health Reform Must Bolster Innovation
Read more
‘It’s possible to have a collective success’: three Geneva health non-profits bolster ties amid shrinking aid
Read more
A meaningful step forward in newborn health in Ghana
Read more
GARDP, Debiopharm to collaborate on new gonorrhea antibiotic
Read more
US FDA approval of Nuzolvence® (zoliflodacin), a first-in-class antibiotic for gonorrhoea
Read more
Antibiotic resistance: how a pioneering trial is using old drugs to save babies from sepsis
Read more
Sharp global rise in antibiotic-resistant infections in hospitals, WHO finds
Read more